M. S. Diamond

This paper computationally redesigns an antibody to restore potency against SARS-CoV-2 Omicron subvariants while maintaining efficacy against Delta and other variants.

This study shows that intestinal helminth infection reduces T cell responses to an mRNA SARS-CoV-2 vaccine and weakens protection against Omicron but not the ancestral strain.

This study shows that Omicron variant-matched boosters after prototype mRNA vaccines induce cross-neutralizing antibodies against SARS-CoV-2 and sarbecoviruses by imprinting prior immune responses.

This study identifies multiple VLDLR binding sites used by EEEV and develops a decoy receptor to neutralize infection.

This paper shows a bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ.1.1 and XBB.1.5 in mice and hamsters through mucosal immunity, despite poor serum neutralizing antibody responses.

This paper evaluates the pathogenicity of SARS-CoV-2 BQ.1.1 and BA.5.5 variants in multiple rodent models, finding increased virulence in transgenic mice but not in conventional mice or hamsters.

This study shows that SARS-CoV-2 boosting induces GC B cell responses and that Omicron-based vaccines can elicit novel epitope-specific antibodies despite antigenic imprinting.

This study shows that Fc-gamma receptor-dependent antibody effector functions are necessary for vaccine protection against antigenic variants of SARS-CoV-2, including Omicron.

The paper develops and evaluates an mRNA vaccine, mRNA-1283, encoding SARS-CoV-2 spike N-terminal and receptor-binding domains, showing improved immunogenicity and protection against multiple variants in mice.

This study evaluates bivalent SARS-CoV-2 mRNA vaccines and finds they induce broader neutralizing antibodies and better protection against BA.5 Omicron compared to monovalent vaccines.

The paper identifies novel innate immune regulators affecting influenza virus replication and pathogenesis through experimental validation of network model predictions.

The paper identifies a multitrait locus on mouse Chromosome 9 that regulates SARS-CoV, SARS-CoV-2, and bat sarbecovirus disease severity, with candidate genes CCR9 and CXCR6.

This study evaluates the effectiveness of S309 and AZD7442 monoclonal antibodies against Omicron variants in mice, showing reduced lung infection despite decreased neutralization in vitro.

This study shows that boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibodies and protection against B.1.1.529 in mice, with the Omicron-matched booster showing slightly better outcomes.

This study compares neutralizing antibody responses to SARS-CoV-2 variants in vaccinated humans and mice, finding that mice do not accurately reflect the breadth and potency seen in humans.

This study shows that nasal delivery of IFN-λ protects mice against SARS-CoV-2 variants including Omicron in both upper and lower respiratory tracts without causing excessive inflammation.

The paper identifies a rare antibody that targets the SARS-CoV-2 spike trimer interface, disrupting viral entry and providing protection in mice.

The paper identifies and characterizes an antibody cocktail, IMM-BCP-01, that neutralizes SARS-CoV-2 variants in vitro and inhibits infection in vivo through Spike Trimer dissociation and effector responses.

This study shows that a combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in rhesus macaques and neutralizes variants of concern in vitro.

This study evaluates the protective efficacy of mRNA vaccines against SARS-CoV-2 variants in mice, showing that low-dose vaccines lead to breakthrough infections with Delta variant.

The paper identifies host susceptibility loci for SARS-CoV and SARS-CoV-2 using GWAS and Collaborative Cross datasets, validating CCR9 as a key regulator of severe disease outcomes across species.

This study shows that an intranasal vaccine provides durable protection against SARS-CoV-2 variants in mice, including emerging strains like B.1.351 and B.1.1.28.

The paper identifies public antibody clonotypes in SARS-CoV-2 convalescents and vaccinated individuals, revealing common epitope recognition and potential vaccine efficacy mechanisms.

A vaccine-induced human monoclonal antibody neutralizes SARS-CoV-2 and variants, reducing lung inflammation and viral load in hamsters.

This study evaluates the protective efficacy of modified miniproteins against SARS-CoV-2 in mice, showing reduced viral burden and prevention of lung disease.

A single intranasal dose of ChAd-SARS-CoV-2-S vaccine protects against SARS-CoV-2 infection in rhesus macaques by inducing neutralizing antibodies and T cell responses.

This paper develops a trans-complementation system to produce single-round infectious SARS-CoV-2 at BSL-2 labs, enabling safe high-throughput testing without full viral replication.

The paper identifies cross-reactive antibodies against multiple coronaviruses, showing they target diverse epitopes and mediate effector functions.

The paper identifies CH25H and its product 25HC as inhibitors of SARS-CoV-2 replication by blocking membrane fusion.